Khondrion features in new video from Catalyze-Group®

find more articles

Khondrion Appoints Jasper Levink as New CEO to Lead Next Phase of Growth

Khondrion and Medvisis Announce Exclusive Licensing Agreement to Commercialize Sonlicromanol for Primary Mitochondrial Diseases in Switzerland and Liechtenstein

Khondrion Secures EU Orphan Drug Designation for Lead Compound Sonlicromanol in Treatment of Inherited Mitochondrial Oxidative Phosphorylation Defects

view all articles